恒力石化(600346.SH):擬分拆所屬子公司康輝新材重組上市
格隆匯7月4日丨恒力石化(600346.SH)公佈,公司擬分拆所屬子公司康輝新材重組上市。本次分拆完成後,康輝新材將成為大連熱電的子公司,大連熱電將會成為康輝新材控股股東,恒力石化將成為康輝新材的間接控股股東。本次分拆事項不會導致公司喪失對康輝新材的控制權。
通過本次分拆上市,公司將進一步聚焦囊括煉化和石化全產業鏈上、中、下游業務領域涉及的PX、醋酸、PTA、乙二醇、民用滌綸長絲、工業滌綸長絲等產品的生產、研發和銷售。康輝新材將成為獨立上市平台,有利於功能性膜材料、高性能工程塑料和生物可降解材料業務的盈利能力和綜合競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.